Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Study

Estimation of breast cancer overdiagnosis in a U.S. breast screening cohort.

Ryser MD, Lange J, Inoue LYT, et al. Estimation of breast cancer overdiagnosis in a U.S. breast screening cohort. Ann Intern Med. 2022;175(4):471-478. doi:10.7326/m21-3577.

Save
Print
March 16, 2022
Ryser MD, Lange J, Inoue LYT, et al. Ann Intern Med. 2022;175(4):471-478.
View more articles from the same authors.

Overdiagnosis of breast cancer can result in overtreatment and cause physical and emotional harm. Based on data from 35,986 women in a US-based breast cancer screening registry, this study estimates that15.4% of screen-detected cancers are overdiagnosed (i.e., detecting indolent preclinical cancer or detecting progressive preclinical cancer among women who would have died of unrelated causes before clinical diagnosis), which is higher than previous estimates. The authors suggest that data can improve shared decision-making between patients and physicians.

Save
Print
Cite
Citation

Ryser MD, Lange J, Inoue LYT, et al. Estimation of breast cancer overdiagnosis in a U.S. breast screening cohort. Ann Intern Med. 2022;175(4):471-478. doi:10.7326/m21-3577.